Skip to main content
. 2022 May 19;15(5):626. doi: 10.3390/ph15050626

Figure 1.

Figure 1

Overview of metformin’s systemic effects on tumor growth. Metformin’s activation of the LKB1/AMPK pathway in hepatocytes and adipocytes, and in the pancreas, leads to reduced blood glucose and insulin availability, respectively. Decreased glucose and insulin availability can slow tumor growth and progression. LKB1: Liver Kinase B1, AMPK: AMP-Activated Protein Kinase. Created in BioRender.